New patent issued for core rare disease target indication for crofelemer
New patent issued for core rare disease target indication for crofelemer
New patent issued for core rare disease target indication for crofelemer
New patent issued for core rare disease target indication for crofelemer
Jaguar to report pivotal phase 3 OnTarget trial results for its cancer supportive care drug crofelemer on or before July 23, 2024
Jaguar to report pivotal phase 3 OnTarget trial results for its cancer supportive care drug crofelemer on or before July 23, 2024
The combined net Q1 2024 revenue of approximately $2.4 million for prescription and non-prescription products increased approximately 20% versus net Q1 2023 revenue of $2.0 million and increased approximately...
Stage II completed; comprehensive results expected in Q1 2024; company's planned regulatory pathway for FDA approval remains on track
To register for the webinar, click here
SAN FRANCISCO, CA / ACCESSWIRE / December 6, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that the abstract for "More Than a Diagnosis: A Quality...